Plerixafor salvage is safe and effective in hard-to-mobilize patients undergoing chemotherapy and filgrastim-based peripheral blood progenitor cell mobilization

Farrukh T. Awan, S. Thomas Kochuparambil, David Deremer, Aaron Cumpston, Michael Craig, Anand Jillella, Mehdi Hamadani

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The combination of filgrastim (G-CSF) and plerixafor is currently approved for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin lymphoma and multiple myeloma undergoing autologous peripheral blood hematopoietic cell transplantation. However, chemotherapy and G-CSF-based mobilization remains a widely used strategy for peripheral blood progenitor cell collection. In this paper we describe our experience from two North American transplant centers in a series of patients who received salvage plerixafor while failing chemotherapy and G-CSF mobilization. Patients received a median of two doses of plerixafor salvage upon failure to mobilize adequate number of peripheral blood progenitor cells at neutrophil recovery. The use of plerixafor was associated with a 2.4-fold increase in peripheral blood CD34+ cell count and 3.9-fold increase in total CD34+ cell yield. All patients were able to collect 2 × 10 6 CD34+cells/kg with this approach. These results were more pronounced in patients with a higher CD34+ cell count at the time of the first plerixafor dose. Interestingly, peripheral blood white blood cell count was not shown to correlate with a response to plerixafor. Our results provide safety and efficacy data for the use of plerixafor in patients who are destined to fail chemomobilization.

Original languageEnglish (US)
Article number931071
JournalJournal of Oncology
DOIs
StatePublished - May 21 2012

Fingerprint

Blood Cells
Stem Cells
Drug Therapy
Granulocyte Colony-Stimulating Factor
Blood Cell Count
Cell Transplantation
Filgrastim
JM 3100
Multiple Myeloma
Leukocyte Count
Non-Hodgkin's Lymphoma
Neutrophils
Cell Count
Transplants
Safety

ASJC Scopus subject areas

  • Oncology

Cite this

Plerixafor salvage is safe and effective in hard-to-mobilize patients undergoing chemotherapy and filgrastim-based peripheral blood progenitor cell mobilization. / Awan, Farrukh T.; Kochuparambil, S. Thomas; Deremer, David; Cumpston, Aaron; Craig, Michael; Jillella, Anand; Hamadani, Mehdi.

In: Journal of Oncology, 21.05.2012.

Research output: Contribution to journalArticle

@article{443e033b06f1400fa9efddb5ad8212dd,
title = "Plerixafor salvage is safe and effective in hard-to-mobilize patients undergoing chemotherapy and filgrastim-based peripheral blood progenitor cell mobilization",
abstract = "The combination of filgrastim (G-CSF) and plerixafor is currently approved for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin lymphoma and multiple myeloma undergoing autologous peripheral blood hematopoietic cell transplantation. However, chemotherapy and G-CSF-based mobilization remains a widely used strategy for peripheral blood progenitor cell collection. In this paper we describe our experience from two North American transplant centers in a series of patients who received salvage plerixafor while failing chemotherapy and G-CSF mobilization. Patients received a median of two doses of plerixafor salvage upon failure to mobilize adequate number of peripheral blood progenitor cells at neutrophil recovery. The use of plerixafor was associated with a 2.4-fold increase in peripheral blood CD34+ cell count and 3.9-fold increase in total CD34+ cell yield. All patients were able to collect 2 × 10 6 CD34+cells/kg with this approach. These results were more pronounced in patients with a higher CD34+ cell count at the time of the first plerixafor dose. Interestingly, peripheral blood white blood cell count was not shown to correlate with a response to plerixafor. Our results provide safety and efficacy data for the use of plerixafor in patients who are destined to fail chemomobilization.",
author = "Awan, {Farrukh T.} and Kochuparambil, {S. Thomas} and David Deremer and Aaron Cumpston and Michael Craig and Anand Jillella and Mehdi Hamadani",
year = "2012",
month = "5",
day = "21",
doi = "10.1155/2012/931071",
language = "English (US)",
journal = "Journal of Oncology",
issn = "1687-8450",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Plerixafor salvage is safe and effective in hard-to-mobilize patients undergoing chemotherapy and filgrastim-based peripheral blood progenitor cell mobilization

AU - Awan, Farrukh T.

AU - Kochuparambil, S. Thomas

AU - Deremer, David

AU - Cumpston, Aaron

AU - Craig, Michael

AU - Jillella, Anand

AU - Hamadani, Mehdi

PY - 2012/5/21

Y1 - 2012/5/21

N2 - The combination of filgrastim (G-CSF) and plerixafor is currently approved for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin lymphoma and multiple myeloma undergoing autologous peripheral blood hematopoietic cell transplantation. However, chemotherapy and G-CSF-based mobilization remains a widely used strategy for peripheral blood progenitor cell collection. In this paper we describe our experience from two North American transplant centers in a series of patients who received salvage plerixafor while failing chemotherapy and G-CSF mobilization. Patients received a median of two doses of plerixafor salvage upon failure to mobilize adequate number of peripheral blood progenitor cells at neutrophil recovery. The use of plerixafor was associated with a 2.4-fold increase in peripheral blood CD34+ cell count and 3.9-fold increase in total CD34+ cell yield. All patients were able to collect 2 × 10 6 CD34+cells/kg with this approach. These results were more pronounced in patients with a higher CD34+ cell count at the time of the first plerixafor dose. Interestingly, peripheral blood white blood cell count was not shown to correlate with a response to plerixafor. Our results provide safety and efficacy data for the use of plerixafor in patients who are destined to fail chemomobilization.

AB - The combination of filgrastim (G-CSF) and plerixafor is currently approved for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin lymphoma and multiple myeloma undergoing autologous peripheral blood hematopoietic cell transplantation. However, chemotherapy and G-CSF-based mobilization remains a widely used strategy for peripheral blood progenitor cell collection. In this paper we describe our experience from two North American transplant centers in a series of patients who received salvage plerixafor while failing chemotherapy and G-CSF mobilization. Patients received a median of two doses of plerixafor salvage upon failure to mobilize adequate number of peripheral blood progenitor cells at neutrophil recovery. The use of plerixafor was associated with a 2.4-fold increase in peripheral blood CD34+ cell count and 3.9-fold increase in total CD34+ cell yield. All patients were able to collect 2 × 10 6 CD34+cells/kg with this approach. These results were more pronounced in patients with a higher CD34+ cell count at the time of the first plerixafor dose. Interestingly, peripheral blood white blood cell count was not shown to correlate with a response to plerixafor. Our results provide safety and efficacy data for the use of plerixafor in patients who are destined to fail chemomobilization.

UR - http://www.scopus.com/inward/record.url?scp=84861042264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861042264&partnerID=8YFLogxK

U2 - 10.1155/2012/931071

DO - 10.1155/2012/931071

M3 - Article

JO - Journal of Oncology

JF - Journal of Oncology

SN - 1687-8450

M1 - 931071

ER -